Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.

Vascular endothelial-cadherin (VE-cadherin) is an endothelial cell-specific adhesion molecule that is localized exclusively at cell-cell contacts referred to as adherens junctions. VE-cadherin-mediated adhesion is crucial for proper assembly of vascular structures during angiogenesis as well as for maintenance of a normal vascular integrity. We have shown previously that a monoclonal antibody (BV13) to VE-cadherin not only inhibits the formation of vascular tubes during tumor angiogenesis but also disrupts adherens junctions of normal vasculature with a concomitant increase in vascular permeability. The goal of the current studies was to block VE-cadherin function during angiogenesis without disrupting existing junctions on normal endothelium. Using in vitro screening assays to test for functional blocking of adherens junction formation and in vivo assays to detect antibody effects on vascular permeability in normal tissues, we have identified a novel blocking antibody (E4G10) that inhibits VE-cadherin function during angiogenesis but does not disrupt existing adherens junctions on normal vasculature. E4G10 inhibited formation of vascular tubes in vivo in the Matrigel plug and corneal micropocket assays. E4G10 also inhibited tumor growth in three models of mouse and human tumors via an antiangiogenic mechanism. Examination of normal mouse and tumor tissues showed that E4G10 bound to endothelial cells in a subset of tumor vasculature but not to normal vasculature. Bromodeoxyuridine labeling experiments showed that E4G10 specifically targeted a subset of tumor endothelium that is undergoing active cell proliferation, which likely reflects the activated, angiogenic endothelium. These findings indicate that VE-cadherin can be selectively targeted during states of pathological angiogenesis, despite its ubiquitous distribution throughout the entire vasculature. Our data also suggest that antibody E4G10 recognizes VE-cadherin epitopes that are only accessible on endothelial cells forming new adherens junctions, such as in angiogenic tumor vasculature.

[1]  C. Kay,et al.  Multiple cadherin extracellular repeats mediate homophilic binding and adhesion , 2001, The Journal of cell biology.

[2]  D. McDonald,et al.  Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. , 2001, The American journal of pathology.

[3]  D. Hicklin,et al.  Monoclonal antibody strategies to block angiogenesis. , 2001, Drug discovery today.

[4]  M. Corada,et al.  Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. , 2001, Blood.

[5]  J W Smith,et al.  Integrin activation controls metastasis in human breast cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  L. Zanetta,et al.  Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. , 2000, Cancer research.

[7]  L. Zuckier,et al.  Influence of affinity and antigen density on antibody localization in a modifiable tumor targeting model. , 2000, Cancer research.

[8]  D. Leckband,et al.  Mechanism of homophilic cadherin adhesion. , 2000, Current opinion in cell biology.

[9]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[10]  D. Leckband,et al.  Direct molecular force measurements of multiple adhesive interactions between cadherin ectodomains. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Lampugnani,et al.  Endothelial adhesion molecules in the development of the vascular tree: the garden of forking paths. , 1999, Current opinion in cell biology.

[12]  M. Corada,et al.  Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  P. Carmeliet,et al.  Targeted Deficiency or Cytosolic Truncation of the VE-cadherin Gene in Mice Impairs VEGF-Mediated Endothelial Survival and Angiogenesis , 1999, Cell.

[14]  A. Ramaswamy,et al.  Elevated expression of endoglin, a component of the TGF‐β‐receptor complex, correlates with proliferation of tumor endothelial cells , 1999, International journal of cancer.

[15]  D. Grant,et al.  VE-Cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. , 1998, Experimental cell research.

[16]  Mihaela Skobe,et al.  Halting angiogenesis suppresses carcinoma cell invasion , 1997, Nature Medicine.

[17]  E. Keshet,et al.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  C. Garlanda,et al.  A general strategy for isolation of endothelial cells from murine tissues. Characterization of two endothelial cell lines from the murine lung and subcutaneous sponge implants. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[19]  M. Humphries,et al.  Integrin activation: the link between ligand binding and signal transduction. , 1996, Current opinion in cell biology.

[20]  M. Corada,et al.  Inhibition of cultured cell growth by vascular endothelial cadherin (cadherin-5/VE-cadherin). , 1996, The Journal of clinical investigation.

[21]  M. Ikura,et al.  Structural basis of calcium-induced E-cadherin rigidification and dimerization , 1996, Nature.

[22]  A. Clowes,et al.  Regulation and function of an activation-dependent epitope of the beta 1 integrins in vascular cells after balloon injury in baboon arteries and in vitro. , 1996, The American journal of pathology.

[23]  M. Corada,et al.  Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[24]  B. Geiger,et al.  The molecular organization of endothelial cell to cell junctions: differential association of plakoglobin, beta-catenin, and alpha- catenin with vascular endothelial cadherin (VE-cadherin) , 1995, The Journal of cell biology.

[25]  Peter D. Kwong,et al.  Structural basis of cell-cell adhesion by cadherins , 1995, Nature.

[26]  L. Samelson.  Iodination of Soluble and Membrane‐Bound Proteins , 1994, Current protocols in immunology.

[27]  C. Garlanda,et al.  Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[29]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[30]  W. Thompson,et al.  Tumours acquire their vasculature by vessel incorporation, not vessel ingrowth , 1987, The Journal of pathology.

[31]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .

[32]  E. Dejana,et al.  Perspectives Series: Cell Adhesion in Vascular Biology Endothelial Adherens Junctions: Implications in the Control of Vascular Permeability and Angiogenesis , 1996 .